Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis

Drug Name

Taltz (ixekizumab)

Developer

Eli Lilly and Company

Therapy Class

Monoclonal antibody

Product Description

Humanized interleukin-17A antagonist

Current Indication

Non-Radiographic Axial Spondyloarthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis

Market Sector

Immunology

Development Status

Approved in the US, Europe, Canada and Japan
Expand
Close
Close
Close

Go Top